PSX ANALYSIS 14 November 2026
Haleon Pakistan Stock Analysis: Profits Rose Nearly 20× — But Is the Stock Worth Buying?

Table of contents13 sections
Haleon Pakistan Stock Analysis: Profits Rose Nearly 20× — But Is the Stock Worth Buying?
Haleon Pakistan Limited (PSX: HALEON), the company behind household names such as Panadol, Sensodyne, CaC-1000 Plus, and Centrum, has experienced an extraordinary recovery in profitability.
In 2022, the company earned just Rs 325 million in net profit. By 2025, that figure had climbed to Rs 6.37 billion — nearly 20 times higher in only three years.
But here is the interesting part: during the same period, revenue increased by only 57%.
How did Haleon increase its profits so dramatically without a corresponding rise in sales? More importantly, is this profitability sustainable, and does the current valuation offer attractive returns for long-term investors?
To answer these questions, I examined Haleon’s annual financial statements from 2021 to 2025 and its latest reported results through September 2026.
The findings reveal a company with valuable brands, a strong balance sheet, and substantially improved profit margins. However, declining revenue, rising inventory, and weakening cash generation raise questions that investors should not ignore.
My central argument is simple: Haleon may be an excellent business, but that does not automatically make its shares an excellent investment at every price.
1. Understanding Haleon Pakistan’s Business
Haleon Pakistan operates in the consumer healthcare sector, manufacturing, marketing, and distributing products across pain relief, oral healthcare, vitamins, minerals, and other healthcare categories.
Its portfolio includes some of the most recognisable consumer healthcare brands in Pakistan:
- Panadol: A widely recognised brand for pain relief and fever management.
- Sensodyne: A leading toothpaste brand focused on tooth sensitivity.
- CaC-1000 Plus: An established calcium supplement brand.
- Centrum: An internationally recognised vitamins and minerals brand.
- Parodontax: An oral healthcare brand targeting gum health.
These brands are important because consumer healthcare is not solely a price-driven industry.
Brand recognition, consumer trust, distribution networks, and established purchasing habits can give companies meaningful competitive advantages.
Haleon also benefits from its association with the global Haleon group and its local manufacturing operations, including the Jamshoro facility.
Together, these advantages provide a foundation for long-term profitability.
However, even a company with established brands must demonstrate that it can grow earnings, generate cash, and reinvest profitably.
And that is where Haleon’s financial history becomes particularly interesting.
2. Five Years of Financial Performance: An Extraordinary Transformation
The following table summarises Haleon’s financial performance between 2021 and 2025.
| Year | Revenue (Rs bn) | Net Profit (Rs bn) | EPS (Rs) |
|---|---|---|---|
| 2021 | 24.16 | 2.13 | 18.23 |
| 2022 | 27.51 | 0.33 | 2.78 |
| 2023 | 31.61 | 1.00 | 8.51 |
| 2024 | 37.21 | 4.58 | 39.11 |
| 2025 | 43.11 | 6.37 | 54.45 |
Revenue increased from Rs 24.16 billion in 2021 to Rs 43.11 billion in 2025, representing a compound annual growth rate of approximately 15.6%.
For an established consumer healthcare company, that is respectable nominal growth.
But the real story is profitability.
Haleon’s earnings per share fell to just Rs 2.78 in 2022 before recovering to Rs 54.45 in 2025.
Such an extraordinary increase in earnings demands closer examination.
Was this the result of a structural improvement in the business, favourable economic conditions, better pricing, or a combination of several factors?
Understanding the answer is essential because the sustainability of future earnings matters far more to investors than the speed of the historical recovery.
3. What Caused the Profit Collapse in 2022 — and the Recovery That Followed?
Haleon’s 2022 results illustrate how quickly profitability can deteriorate when economic conditions turn unfavourable.
Pakistan was experiencing significant currency depreciation, inflation, rising imported input costs, and pressure on pharmaceutical pricing.
For businesses that depend on imported raw materials or packaging, these conditions can compress margins considerably.
Haleon’s gross profit margin tells the story.
| Year | Gross Profit Margin |
|---|---|
| 2021 | 27.7% |
| 2022 | 17.4% |
| 2023 | 20.4% |
| 2024 | 34.5% |
| 2025 | 39.1% |
In 2022, Haleon’s gross margin collapsed to 17.4%, compared with 27.7% a year earlier.
The company was generating revenue, but a much larger share of that revenue was being consumed by production costs.
However, the recovery between 2023 and 2025 was equally dramatic.
One important development was the government’s 2024 decision to deregulate prices for eligible medicines outside the World Health Organization’s essential medicines list.
This provided greater pricing flexibility for qualifying products, potentially improving profitability.
More favourable input costs, operational efficiencies, and changes in product mix may also have contributed to Haleon’s recovery, although the financial disclosures do not establish the precise contribution of each factor.
Why Small Changes in Margins Matter So Much
Consider Haleon’s 2025 revenue of approximately Rs 43.11 billion.
At that revenue level, a one-percentage-point improvement in gross profit margin translates into approximately Rs 431 million in additional gross profit, before operating expenses and taxation.
This explains how earnings can increase much faster than revenue.
But the same mechanism works in reverse.
If input costs rise, pricing flexibility weakens, or competition intensifies, even a relatively modest deterioration in margins can substantially reduce earnings.
For a long-term investor, the critical question is therefore not whether Haleon can repeat its extraordinary recovery.
It is whether the company can maintain gross margins close to their current levels over the next five to ten years.
4. The 2026 Results: Profits Are Holding Up, but Sales Are Declining
Haleon’s results for the first nine months of 2026 introduce a more complicated picture.
| Financial Metric | 9M 2025 | 9M 2026 |
|---|---|---|
| Revenue | Rs 32.19bn | Rs 29.66bn |
| Gross Profit | Rs 12.36bn | Rs 12.40bn |
| Net Profit | Rs 4.59bn | Rs 4.73bn |
| EPS | Rs 39.18 | Rs 40.40 |
Two developments stand out.
First, revenue declined by approximately 7.9%.
Second, despite lower revenue, net profit increased by approximately 3.1%.
At first glance, this suggests that Haleon has developed a more resilient business.
Its gross margin improved from approximately 38.4% to 41.8%, allowing the company to maintain gross profit despite the decline in sales.
That is encouraging from a profitability perspective.
However, falling revenue is not something investors should overlook indefinitely.
A company can preserve earnings through higher margins and cost reductions for some time, but sustainable long-term growth eventually requires healthy demand, pricing, or both.
There are also important adjustments behind the reported numbers.
The Rs 640 Million Accounting Adjustment
Haleon’s September 2026 financial statements disclose a customs-related accrued-liability adjustment of approximately Rs 640 million following a favourable Supreme Court decision.
This benefited reported profitability but does not represent recurring revenue or an improvement in manufacturing efficiency.
The company also reported approximately Rs 396 million in restructuring expenses, recognised within cost of sales and selling and distribution expenses.
To get a clearer view of recurring profitability, we can make an illustrative adjustment:
- Remove the approximately Rs 640 million customs-related benefit.
- Add back the approximately Rs 396 million in identified restructuring expenses.
On this basis, adjusted profit before tax for the first nine months of 2026 would be approximately Rs 7.27 billion, compared with reported profit before tax of approximately Rs 7.56 billion in the corresponding period of 2025.
This is my analytical adjustment, not a company-reported measure of underlying earnings. It also excludes potential tax effects and other adjustments.
Nevertheless, it suggests that underlying profitability may be somewhat weaker than the headline increase in EPS indicates.
Marketing Expenditure Has Also Declined
Another noteworthy development is the reduction in advertising and sales promotion expenditure.
During the first nine months of 2025, Haleon spent approximately Rs 2.69 billion on advertising and promotion.
That figure declined to around Rs 2.09 billion in the corresponding period of 2026 — a reduction of approximately 22.5%.
Reducing unnecessary expenditure can improve profitability. However, consumer healthcare brands depend heavily on recognition, trust, and continued engagement with consumers.
Lower advertising expenditure is not automatically negative, particularly if the company is improving marketing efficiency.
But investors should monitor whether these reductions are accompanied by weaker sales volumes or declining market share.
Ultimately, Haleon needs to demonstrate that it can maintain profitability without sacrificing its longer-term growth prospects.
5. Inventory Is Rising Much Faster Than Sales
One of the most concerning developments in Haleon’s recent financial statements is the substantial increase in inventory.
| Period | Net Inventory |
|---|---|
| December 2024 | Rs 5.04bn |
| December 2025 | Rs 7.70bn |
| September 2026 | Rs 11.91bn |
Inventory increased by approximately 55% in the first nine months of 2026, even as reported revenue declined.
A significant portion consists of raw and packing materials, including materials in transit.
There could be reasonable explanations for this increase.
The company may be accumulating raw materials to support manufacturing expansion, protecting itself against supply disruptions, or purchasing imported materials ahead of anticipated requirements.
These are plausible explanations, but they should not be treated as established facts without further disclosure.
Another possibility is that slower demand is contributing to weaker inventory turnover.
The distinction matters.
If inventory accumulation is related to planned production expansion, it may eventually support higher sales and improved operating efficiency.
However, if it reflects slower inventory movement, the company could face greater working-capital requirements and potentially higher storage or obsolescence risks.
Investors should therefore monitor whether inventory begins to normalise relative to sales.
The important point is that inventory is not just an accounting number. It represents cash tied up in the business.
And that leads to what I consider one of the most important concerns in Haleon’s financial statements.
6. Cash Flow: Are Reported Profits Turning Into Actual Cash?
Profitability and cash generation are closely related, but they are not the same thing.
A business can report strong accounting earnings while simultaneously consuming significant amounts of cash through inventory, receivables, or capital expenditure.
Haleon’s operating cash flow provides a useful illustration.
| Period | Operating Cash Flow |
|---|---|
| 2023 | Rs 2.08bn |
| 2024 | Rs 6.64bn |
| 2025 | Rs 5.58bn |
| 9M 2026 | Rs 1.30bn |
In 2024, the company generated more operating cash flow than its reported net profit.
That was a positive sign.
However, cash generation weakened in 2025 despite higher earnings.
The divergence became particularly pronounced during the first nine months of 2026.
Haleon reported approximately Rs 4.73 billion in net profit but generated only Rs 1.30 billion in operating cash flow.
That means operating cash flow represented only 27% of reported net profit.
This is a substantial gap.
The increase in inventory has been an important contributor to the absorption of cash into working capital.
What Happens After Capital Expenditure?
Operating cash flow is only part of the equation.
Businesses also need to spend money maintaining and expanding their manufacturing operations.
During the first nine months of 2026, Haleon spent approximately Rs 1.39 billion on property, plant, and equipment.
Subtracting this expenditure from operating cash flow produces slightly negative simplified free cash flow of approximately Rs 0.1 billion.
In other words, despite reporting nearly Rs 4.73 billion in accounting profit, the company generated little free cash after these capital investments during the period.
This does not necessarily mean that Haleon is experiencing financial distress.
The cash-flow weakness may be temporary, particularly if inventory accumulation and manufacturing investments are part of a planned expansion.
However, the pattern needs to improve.
Over a five-to-ten-year investment horizon, shareholders ultimately benefit from the cash a company can generate and distribute or reinvest profitably.
If reported earnings continue to grow without a corresponding improvement in cash flow, the quality and sustainability of those earnings deserve greater scrutiny.
7. A Strong Balance Sheet Provides Important Protection
Despite concerns about working capital, Haleon’s financial position remains one of its principal strengths.
As of September 30, 2026, the company reported approximately:
| Balance Sheet Item | Amount |
|---|---|
| Cash and investments | Rs 6.10bn |
| Bank borrowings | Nil |
| Lease liabilities | Rs 0.25bn |
| Shareholders’ equity | Rs 16.60bn |
| Trade and other payables | Rs 11.92bn |
The absence of conventional bank borrowings is particularly attractive.
Companies with substantial debt can experience significant earnings pressure when interest rates rise.
Haleon has relatively limited exposure to that risk because it does not depend heavily on bank financing.
Its cash and investment balances also provide financial flexibility to support operations and planned capital expenditure.
However, the balance sheet should not be interpreted as entirely free of obligations.
Trade and other payables remain substantial, and part of the company’s operations is effectively financed through these liabilities.
Similarly, its Rs 6.10 billion in cash and investments should not automatically be considered surplus funds available for dividends.
The company still needs sufficient liquidity to finance inventory, operating expenses, and manufacturing investments.
Overall, I consider Haleon’s balance sheet a meaningful competitive strength.
But that strength does not eliminate the need to improve cash generation.
8. Jamshoro Manufacturing Expansion: A Potential Long-Term Growth Driver
Haleon has been investing in manufacturing capabilities, particularly at its Jamshoro facility.
These investments could strengthen the company’s competitive position over time.
Greater local manufacturing capacity may help improve supply reliability, reduce dependence on imported finished products, increase production volumes, and potentially lower unit costs.
As of September 2026, the company also disclosed approximately Rs 1.57 billion in outstanding capital expenditure commitments.
This indicates that manufacturing investment remains an important part of its operating plans.
However, capital expenditure should not be confused with value creation.
A manufacturing facility creates economic value only when the additional returns justify the investment.
For Haleon, I would focus on three questions.
Will the investment generate meaningful additional revenue? Will it improve manufacturing efficiency and sustainable profit margins? And, most importantly, will the additional earnings translate into stronger operating cash flow?
If the answer to these questions becomes clear in future results, Haleon’s long-term earnings potential could improve.
Until then, I would regard the expansion as an opportunity rather than assume that higher capital expenditure will automatically result in higher shareholder returns.
9. Haleon Pakistan Valuation: What Is a Reasonable Share Price?
Having examined the business, the next question is valuation.
Haleon has strong brands, a healthy balance sheet, and substantially improved profitability.
However, these characteristics are already reflected to some extent in the price investors are willing to pay.
For valuation purposes, I prefer using sustainable earnings rather than assuming that the extraordinary growth between 2022 and 2025 can continue indefinitely.
My illustrative earnings and valuation assumptions for 2027 are:
| Scenario | EPS (Rs) | Assumed P/E | Estimated Value |
|---|---|---|---|
| Bear | 48 | 9× | Rs 432 |
| Base | 55 | 11× | Rs 605 |
| Bull | 62 | 13× | Rs 806 |
These estimates are not guaranteed price targets. They illustrate how a company’s valuation can change depending on its sustainable earnings and the multiple investors are willing to pay for those earnings.
Bear Case: Rs 432
In the bearish scenario, earnings weaken to Rs 48 per share and the market assigns a relatively conservative P/E multiple of 9.
This could occur if revenue weakness persists, profitability comes under pressure, or investors become less willing to pay a premium for the company.
Base Case: Rs 605
My base case assumes earnings of approximately Rs 55 per share and a valuation multiple of 11.
This reflects a business that maintains much of its improved profitability but experiences relatively moderate earnings growth.
At these assumptions, I arrive at an illustrative value of approximately Rs 605 per share.
Bull Case: Rs 806
The bullish scenario assumes EPS of Rs 62 and a P/E multiple of 13.
Achieving this outcome would likely require stronger revenue performance, continued healthy margins, improved working-capital efficiency, and greater investor confidence in future growth.
How Does This Compare With the Market Price?
Haleon’s share price was approximately Rs 696 on November 12, 2026.
At that price, the stock traded above my base-case value of Rs 605 but below the bullish valuation of Rs 806.
This suggests that investors purchasing at that level are paying for at least some expectation of future improvement.
If earnings remain relatively stagnant or the market assigns a lower valuation multiple, returns could be disappointing.
This is why I would not evaluate Haleon solely on its historical profit recovery.
The more relevant consideration is how much future growth is already reflected in its share price.
10. What Returns Could Investors Expect Over Five Years?
A one-year valuation is useful, but my investment approach is primarily focused on longer holding periods.
To understand how the purchase price influences long-term returns, consider a simplified five-year scenario.
Assume that Haleon:
- Earns Rs 75 per share in the fifth year.
- Distributes a cumulative Rs 175 per share in dividends during the holding period.
- Trades at an exit P/E multiple of 9, 11, or 13.
Using these assumptions, the approximate annualised equivalent total returns would be:
| Purchase Price | Exit P/E 9× | Exit P/E 11× | Exit P/E 13× |
|---|---|---|---|
| Rs 500 | 11.2% | 14.9% | 18.1% |
| Rs 540 | 9.5% | 13.1% | 16.3% |
| Rs 600 | 7.2% | 10.8% | 13.9% |
| Rs 696 | 4.1% | 7.5% | 10.6% |
These are simplified annualised equivalent returns calculated using the final share value plus cumulative dividends. They assume dividends are retained without reinvestment and do not model the timing of individual payouts. Actual annualised returns will differ depending on dividend timing, taxes, transaction costs, and business performance.
This table highlights one of the most important principles of investing.
You can correctly identify a good company and still earn disappointing returns if you pay too much for its shares.
At a purchase price of Rs 500, the scenario with an exit multiple of 11 offers an illustrative annualised return of approximately 14.9%.
At Rs 696, the same business performance and exit valuation produce an annualised equivalent return of only about 7.5%.
Nothing about the company’s future performance has changed between these two calculations.
The difference comes entirely from the price paid initially.
That is why I place considerable emphasis on valuation discipline and margin of safety.
11. My Preferred Buying Range
Considering Haleon’s financial position, earnings outlook, cash-flow concerns, and potential five-year returns, my preferred accumulation range would be:
Rs 500–540 per share.
At these levels, the stock would offer a more attractive margin of safety against several uncertainties.
These include whether current profit margins can be sustained, whether declining revenue will recover, how quickly inventory will normalise, and whether manufacturing investments will generate satisfactory returns.
Buying within this range would also improve potential long-term returns under my less optimistic valuation assumptions.
However, this is not a prediction that the share price must fall to Rs 500–540.
It is the range at which I would become more interested in evaluating an investment based on the financial information currently available.
If Haleon demonstrates stronger revenue growth, improves operating cash flow, and generates attractive returns on its manufacturing investments, its intrinsic value could increase.
Conversely, if earnings or cash generation deteriorate, even my preferred buying range may need to be revised.
A valuation should evolve with the underlying business rather than remain permanently fixed.
12. Final Verdict: Strong Business, but the Entry Price Matters
After reviewing Haleon’s financial performance, I see a business with several attractive long-term characteristics.
Its brands are well established, its balance sheet is relatively strong, and its limited reliance on bank borrowing provides a meaningful advantage.
The recovery in profitability since 2022 also demonstrates how significantly earnings can improve when pricing and cost conditions become more favourable.
However, I am not entirely comfortable extrapolating that recovery into the future.
The first nine months of 2026 raise several questions.
Revenue has declined, inventory has increased substantially, and cash-flow conversion has weakened. Reported profitability has also benefited from a non-recurring accounting adjustment.
None of these developments necessarily indicates a permanent deterioration in the business.
But together, they justify a more cautious approach to valuation.
Looking ahead, I would pay particular attention to five indicators:
- Revenue and volume growth: Can Haleon return to sustainable sales growth?
- Inventory levels: Does inventory begin to normalise relative to revenue?
- Operating cash flow: Can the company convert a larger proportion of its earnings into cash?
- Profit margins: Are current margins sustainable without relying excessively on cost reductions or one-off benefits?
- Manufacturing returns: Do investments at Jamshoro translate into higher earnings and cash generation?
If these indicators improve, the company’s investment case could become considerably stronger.
For now, my conclusion is that Haleon Pakistan is a high-quality business worth following, but its valuation needs to offer a more attractive balance between potential returns and downside risk before I would consider a substantial investment.
Over a five-to-ten-year horizon, I am not simply looking for companies that can grow.
I am looking for businesses that can grow sustainably, generate cash, reward shareholders, and be purchased at prices that leave room for uncertainty.
Ultimately, the objective is not merely to own a good company.
It is to own a good company at a price that makes it a good investment.
Watch My Complete Haleon Pakistan Analysis
I have also covered Haleon Pakistan’s financial performance, margin recovery, cash-flow concerns, manufacturing investments, earnings forecasts, and valuation scenarios in my YouTube analysis.
Watch my complete Haleon Pakistan stock analysis on YouTube
I would also like to hear your perspective.
Do you believe Haleon’s established brands and strong balance sheet justify a premium valuation, or would you prefer to see stronger revenue growth and cash-flow generation before investing?
Share your thoughts in the comments.
Sources and Disclaimer
Financial sources: Haleon Pakistan Limited annual reports (2021–2025), financial statements for the nine months ended September 30, 2026, and company disclosures available through the Pakistan Stock Exchange.
Disclaimer: This article is intended for educational and informational purposes only. It does not constitute personalised financial advice or a recommendation to buy or sell securities. Earnings forecasts, valuation multiples, dividend assumptions, buying ranges, and projected returns are illustrative and subject to uncertainty. Investors should conduct their own research and consider their individual financial circumstances before making investment decisions.